Motoi Kondo

Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.

Motoi Kondo, Hirofumi Yamamoto, Hiroaki Nagano et al. · PubMed · 1999 · 181 citations

Medicine, Oncology, Pathology +13

Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm

Nobuyasu Hayashi, Hirofumi Yamamoto, Nobuaki Hiraoka et al. · Hepatology · 2001 · 133 citations · Full text

Medicine, Cell Biology, Pathology +11

Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin‐2 and hypoxia‐induced factor‐1a

Hiroshi Wada, Hiroaki Nagano, Hirofumi Yamamoto et al. · Liver International · 2006 · 131 citations

Medicine, Cancer Biology, Oncology +15

JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis

Hirofumi Yamamoto, Motoi Kondo, Shoji Nakamori et al. · Gastroenterology · 2003 · 124 citations

Veterinary Medicine, Pharmacology, Cell Signaling +13

Diagnosis of intrahepatic metastasis and multicentric carcinogenesis by microsatellite loss of heterozygosity in patients with multiple and recurrent hepatocellular carcinomas

Osakuni Morimoto, Hiroaki Nagano, Masato Sakon et al. · Journal of Hepatology · 2003 · 116 citations

Medicine, Genetics, Oncology +17